[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625039":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Ankara City Hospital Bilkent","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Dutasteride Group",null,"Patients who were treated with 0.5 mg\u002Fday dutasteride for at least 6 months prior to the HoLEP surgery.",[13,14],"Drug: Dutasteride","Procedure: Holmium Laser Enucleation of the Prostate (HoLEP)",{"label":16,"type":10,"description":17,"interventionNames":18},"Control Group","Patients who underwent HoLEP surgery but had no history of using 5-alpha reductase inhibitors (5-ARIs) before the procedure.",[14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Dutasteride","Patients in the study group received 0.5 mg\u002Fday of dutasteride for at least 6 months before surgery as part of their routine BPH treatment.",[9],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"PROCEDURE","Holmium Laser Enucleation of the Prostate (HoLEP)","Standard HoLEP procedure performed for the surgical treatment of benign prostatic hyperplasia.",[16,9],[31],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},"Yusuf Gökkurt, MD, Specialist","CONTACT","+905067910557","yusufgokkurt@gmail.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":10,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Ankara Bilkent City Hospital","RECRUITING","Ankara","Universiteler","06800","Turkey (Türkiye)",{"type":45,"coordinates":46},"Point",[47,48],32.85427,39.91987,{"lat":48,"lon":47},[51],{"name":52,"role":33,"phone":53,"phoneExt":10,"email":35},"Yusuf Gökkurt, MD","+90 506 791 0557",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Yusuf Gökkurt","Urology Specialist","100625039","impact-of-long-term-dutasteride-use-on-perioperative-outcomes-of-holep-100625039",false,"NCT07417449","Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEP","The Impact of Long-Term Dutasteride Use on Surgical Outcomes and Perioperative Parameters in Patients Undergoing Holmium Laser Enucleation of the Prostate (HoLEP)","Inclusion Criteria:\n\n* Male patients aged 40 to 80 years.\n* Diagnosed with symptomatic Benign Prostatic Hyperplasia (BPH) and scheduled for elective Holmium Laser Enucleation of the Prostate (HoLEP).\n* For the study group: Documented continuous use of Dutasteride (0.5 mg\u002Fday) for a minimum of 6 months immediately prior to the surgical date.\n* For the control group: No history of 5-alpha reductase inhibitor (5-ARI) use within the last 12 months.\n* Patients with complete medical records available in the Hospital Information Management System (HBYS).\n\nExclusion Criteria:\n\n* Patients with a history of previous prostate surgery or pelvic radiotherapy.\n* Patients diagnosed with prostate adenocarcinoma in the pathology results or those scheduled for a biopsy due to suspicion of prostate cancer prior to the operation.\n* Cases with incomplete data in the hospital's electronic database, including missing operative notes, preoperative\u002Fpostoperative hemoglobin levels, or resected tissue weight.","MALE","40 Years","80 Years",{"count":69,"type":70},1000,"ESTIMATED","OBSERVATIONAL","This study aims to investigate the effects of long-term dutasteride use (a 5-alpha reductase inhibitor) on surgical outcomes in patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP) for benign prostatic hyperplasia (BPH).\n\nWhile some studies suggest that short-term use of these medications can reduce bleeding during surgery, there is limited data on the impact of chronic, long-term use (at least 6 months) specifically during the HoLEP procedure.\n\nThe researchers will retrospectively analyze patient records to compare two groups: those who used dutasteride for 6 months or longer before surgery, and those who did not use any 5-alpha reductase inhibitors. The primary focus is to determine whether long-term dutasteride treatment leads to a significant difference in surgical bleeding (measured by hemoglobin drop), operation time, and the efficiency of removing prostate tissue (morcellation). The findings will help surgeons better understand how preoperative medication history influences the technical aspects of HoLEP surgery.",[74],"Prostatic Hyperplasia, Benign",[76,22,77,78,79],"HoLEP","5-alpha Reductase Inhibitors","Prostate Surgery","Perioperative Bleeding","2026-03-31",{"date":82,"type":83},"2026-04-06","ACTUAL",{"date":85,"type":70},"2026-04-01",{"date":87,"type":70},"2027-04-01",{"name":5,"class":6},1]